Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.33 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.33 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255954 | 0.86 | TSHR (0.44) | TSHRORAI1ORAI2ORAI3HTR2C | |
| Hydrochloric Acid SCHEMBL28694707 | 0.85 | TSHR (0.42) | TSHRORAI1ORAI2ORAI3 | |
| SCHEMBL1376881 | 0.85 | TSHR (0.48) | TSHRORAI1ORAI2ORAI3 | |
| SCHEMBL17058245 | 0.75 | — | — | |
| SCHEMBL7385496 | 0.75 | — | — | |
| SCHEMBL11751309 | 0.75 | ORAI1 (0.41) | TSHRORAI1ORAI2ORAI3HTR2C | |
| SCHEMBL7351101 | 0.73 | PNMT (0.45) | HTR2C | |
| SCHEMBL14275868 | 0.71 | PLAU (0.50) | — | |
| SCHEMBL3493955 | 0.71 | MAOA (0.41) | CES1 | |
| SCHEMBL14275871 | 0.70 | PLAU (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 931 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106675082-A | Method for preparing disperse blue 354 | 江苏道博化工有限公司 | 2017-05-17 | — | — | CN | claimed |
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | claimed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | claimed |
| CN-101489544-A | Method for treating hematological disorders | HEMAQUEST PHARMACEUTICALS INC (US) | 2009-07-22 | — | — | CN | claimed |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| EP-2046755-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | claimed |
| EP-2023913-A2 | METHODS FOR TREATING BLOOD DISORDERS | Colorado State University Research Foundation (US) | 2009-02-18 | — | — | EP | claimed |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2008-03-27 | — | — | US | claimed |
| WO-2008012227-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-31 | — | — | WO | claimed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | claimed |
| US-6362180-B1 | ANTAGONIST TO CORTICOTROPIN RELEASING FACTOR | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-03-26 | — | — | US | claimed |
| EP-1091941-A1 | NOVEL BENZIMIDAZOLES AS CORTICOTROPIN RELEASE FACTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2001-04-18 | — | — | EP | claimed |
| EP-1091961-A1 | IMIDAZO-PYRIDINES, -PYRIDAZINES, AND -TRIAZINES AS CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2001-04-18 | — | — | EP | claimed |
| WO-2000059908-A2 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | claimed |
| WO-2000059907-A2 | PYRAZOLOTRIAZINES AS CRF ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | claimed |
| US-6124463-A | TREATMENT OF AFFECTIVE DISORDER, ANXIETY OR DEPRESSION | DUPONT PHARMACEUTICALS (US) | 2000-09-26 | — | — | US | claimed |
| EP-0994877-A1 | IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Du Pont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | claimed |
| WO-2000001697-A1 | IMIDAZO-PYRIDINES, -PYRIDAZINES, AND -TRIAZINES AS CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-01-13 | — | — | WO | claimed |
| WO-2000001675-A1 | NOVEL BENZIMIDAZOLES AS CORTICOTROPIN RELEASE FACTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-01-13 | — | — | WO | claimed |
| WO-1999001454-A1 | IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-01-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137567-A1 | Methods for Treating Blood Disorders | HBB, HBG1, HBG2 | TSHR 3467/4885ORAI1 4855/4885ORAI2 4321/4885 |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | HBG1, HBG2, HBB | TSHR 1806/4885ORAI1 1792/4885ORAI2 2855/4885 |
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | TSHR 2577/4885ORAI1 4531/4885ORAI2 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.